Business Context and Reporting Period
This Form 8-K Current Report was filed by Inmune Bio, Inc. on April 29, 2019, covering events occurring on April 24, 2019. The company is an emerging growth company incorporated in Nevada.
Key Financial Metrics
This filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The report focuses exclusively on a specific corporate action regarding equity issuance.
Material Changes
The primary event reported is a modification to a Consulting Agreement dated May 16, 2018, between Inmune Bio, Inc. and Pacific Seaboard Investments LTD. Under the original agreement, the company was obligated to issue 600,000 restricted shares of common stock. On April 24, 2019, Pacific Seaboard executed a waiver relinquishing the right to the final 200,000 shares. Consequently, the total issuance to Pacific Seaboard was reduced to 400,000 shares.
Guidance, Outlook, and Risks
The filing contains no management guidance, financial outlook, or discussion of general business risks. The only contingency noted is the execution of the Waiver, which is attached as Exhibit 99.1 and incorporated by reference.
Investor Verification Checklist
- Verify the terms of the original Consulting Agreement dated May 16, 2018.
- Review the attached Waiver (Exhibit 99.1) to confirm the final share count of 400,000.
- Check subsequent filings for the actual issuance of the 400,000 restricted shares.
- Confirm the impact of this reduction on the company's total authorized and outstanding share count.